Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ra Capital Management, L.P. Sells 87,490 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 87,490 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $0.67, for a total value of $58,618.30. Following the completion of the transaction, the insider directly owned 413,001 shares in the company, valued at approximately $276,710.67. This trade represents a 17.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $64,736.64.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total transaction of $267,333.46.

Werewolf Therapeutics Stock Down 4.3%

Werewolf Therapeutics stock opened at $0.63 on Wednesday. The company has a market capitalization of $30.72 million, a PE ratio of -0.51 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 12-month low of $0.53 and a 12-month high of $2.38. The firm’s fifty day moving average is $0.81 and its 200 day moving average is $0.83.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. Sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics in the 2nd quarter valued at about $48,000. Regal Investment Advisors LLC increased its holdings in Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. increased its holdings in Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics in the first quarter worth approximately $79,000. Finally, Susquehanna International Group LLP lifted its holdings in shares of Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares in the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

Analyst Ratings Changes

HOWL has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Werewolf Therapeutics has a consensus rating of “Hold” and an average price target of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.